Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Common Equity (2018 - 2026)

TELA Bio has reported Common Equity over the past 8 years, most recently at $6.3 million for Q4 2025.

  • For Q4 2025, Common Equity fell 77.82% year-over-year to $6.3 million; the TTM value through Dec 2025 reached $6.3 million, down 77.82%, while the annual FY2025 figure was $6.3 million, 77.82% down from the prior year.
  • Common Equity for Q4 2025 was $6.3 million at TELA Bio, up from $1.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $41.7 million in Q1 2021 and troughed at -$6.3 million in Q3 2024.
  • A 5-year average of $16.9 million and a median of $16.3 million in 2024 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 2694.36% in 2023 and later plummeted 120.53% in 2024.
  • Year by year, Common Equity stood at $20.1 million in 2021, then dropped by 28.82% to $14.3 million in 2022, then surged by 31.99% to $18.9 million in 2023, then soared by 50.72% to $28.5 million in 2024, then tumbled by 77.82% to $6.3 million in 2025.
  • Business Quant data shows Common Equity for TELA at $6.3 million in Q4 2025, $1.6 million in Q3 2025, and $9.2 million in Q2 2025.